Bioventus (NASDAQ:BVS) Rating Lowered to “Buy” at Wall Street Zen

Bioventus (NASDAQ:BVS) was downgraded by stock analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a note issued to investors on Saturday, Wall Street Zen reports.

Other analysts also recently issued research reports about the company. Canaccord Genuity Group dropped their price target on Bioventus from $19.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, November 3rd. Craig Hallum restated a “buy” rating and issued a $18.00 price objective on shares of Bioventus in a research report on Thursday, August 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $15.00 target price on shares of Bioventus in a research note on Monday, August 17th. Weiss Ratings downgraded shares of Bioventus from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday. Finally, Barrington Research set a $18.00 target price on shares of Bioventus in a research report on Thursday, August 6th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.60.

Bioventus Price Performance

BVS opened at $10.61 on Friday. The company has a fifty day moving average price of $13.44 and a 200-day moving average price of $10.97. The firm has a market capitalization of $894.00 million, a P/E ratio of 13.26, a price-to-earnings-growth ratio of 1.36 and a beta of 0.66. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.68 and a quick ratio of 1.16. Bioventus has a one year low of $6.47 and a one year high of $15.89.

Bioventus (NASDAQ:BVS) last released its quarterly earnings results on Monday, November 2nd. The company reported $0.17 earnings per share for the quarter, hitting the consensus estimate of $0.17. Bioventus had a net margin of 9.78% and a return on equity of 26.31%. The firm had revenue of $142.44 million for the quarter. Equities research analysts expect that Bioventus will post 0.78 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bioventus

Hedge funds have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP lifted its position in Bioventus by 14.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 873,138 shares of the company’s stock worth $7,971,000 after buying an additional 107,930 shares during the last quarter. Hillsdale Investment Management Inc. boosted its stake in Bioventus by 148.7% in the first quarter. Hillsdale Investment Management Inc. now owns 671,139 shares of the company’s stock worth $6,128,000 after buying an additional 401,230 shares in the last quarter. Engine Capital Management LP bought a new position in Bioventus during the first quarter valued at approximately $2,876,000. Lazard Asset Management LLC grew its position in Bioventus by 12.9% during the first quarter. Lazard Asset Management LLC now owns 305,517 shares of the company’s stock valued at $2,789,000 after acquiring an additional 35,008 shares during the last quarter. Finally, Sei Investments Co. grew its position in Bioventus by 160.7% during the first quarter. Sei Investments Co. now owns 289,648 shares of the company’s stock valued at $2,644,000 after acquiring an additional 178,539 shares during the last quarter. Institutional investors own 62.94% of the company’s stock.

About Bioventus

Bioventus Inc is a medical device and biologics company focused on developing and commercializing products that support bone healing, joint health and surgical recovery. Its portfolio is designed to help healthcare professionals treat musculoskeletal conditions and improve patient outcomes through noninvasive therapies, injectable products and biologic solutions.

The company’s offerings include bone stimulation systems such as EXOGEN, which is used to support fracture healing, as well as injectable osteoarthritis treatments including DUROLANE and GELSYN-3.